![](images/graphics/blank.gif)
Antiangiogenic therapies
-
Despite advancements in managing metastatic clear cell renal carcinoma (mccRCC) through antiangiogenic tyrosine kinase inhibitors and immunotherapy, there remains a demand for novel treatments for patients experiencing progression despite the use of these medications.
8p
vishanshan
27-06-2024
2
1
Download
-
For the first-line treatment of KRAS mutant non-small cell lung cancer (NSCLC) patients, immunotherapy or platinum-based chemotherapy are the main treatment method. Here, we investigated the clinical efcacy and prognosis those two regimens as first-line treatment in real-world practice.
14p
vileonardodavinci
23-12-2023
3
2
Download
-
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: A real-world study
Non-small cell cancer (NSCLC) patients with concomitant epidermal growth factor receptor (EGFR) and TP53 mutations have a poor prognosis with the treatment of tyrosine kinase inhibitors (TKIs), and may benefit from a combination regimen preferentially. The present study aims to compare the benefits of EGFR-TKIs and its combination with antiangiogenic drugs or chemotherapy in patients with NSCLC harboring EGFR and TP53 co-mutation in a reallife setting.
11p
vischultz
20-10-2023
2
1
Download
-
Several studies have demonstrated the antitumor activity of rosiglitazone (RGZ) in cancer cells, including breast cancer cells. However, the molecular targets of RGZ in the inhibition of angiogenesis in breast cancer cells remain unclear.
17p
vihagrid
30-01-2023
5
3
Download
-
Data on efficacy of bevacizumab (B) beyond first-line taxane -including regimen (BT) as first-line treatment are lacking. Although preclinical results that anti-angiogenic agents combined with hormonal therapy (HT) could be active, no clinical data exist about combination of maintenance Bevacizumab (mBev) with HT.
7p
viirene2711
03-10-2020
10
0
Download
-
Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine tumours (NETs). Herein, we investigate the use of these treatment combinations in clinical practice.
11p
viamsterdam
18-09-2020
19
2
Download
-
Preclinical research indicate that vascular disrupting agent (VDA) treatment induces extensive tumor death but also a systemic mobilization of bone marrow derived cells including endothelial progenitor cells (EPC) leading to revascularization and renewed growth within the residual tumor.
11p
vimale2711
25-08-2020
14
2
Download
-
Antiangiogenic therapies are considered promising for the treatment of glioblastoma (GB). The noncollagenous C-terminal globular NC1 domain of type VIII collagen a1 chain, Vastatin, is an endogenous antiangiogenic polypeptide. Sustained enhanced expression of Vastatin was shown to inhibit tumour growth and metastasis in murine hepatocellular carcinoma models. In this study, we further explored the efficacy of Vastatin in the treatment of GB xenografts.
10p
vimale2711
21-08-2020
11
1
Download
-
Vascular supply of tumors is one of the main targets for cancer therapy. Here, we investigated if plocabulin (PM060184), a novel marine-derived microtubule-binding agent, presents antiangiogenic and vascular-disrupting activities.
13p
vibaku2711
22-07-2020
19
1
Download
-
Imidazolium trans-imidazoledimethyl sulfoxide-tetrachlo-roruthenate (NAMI-A) is a novel ruthenium-containing experimental antimetastatic agent. Compelling evidence ascribes apivotal role toendothelial cells in theorchestration of tumor angiogenesis and metastatic growth, suggesting antiangiogenic therapy as an attractive approach for anticancer treatment.
10p
tumor12
22-04-2013
40
1
Download
-
Lederle et al. EJNMMI Research 2011, 1:26 http://www.ejnmmires.com/content/1/1/26 ORIGINAL RESEARCH Open Access Failure of annexin-based apoptosis imaging in the assessment of antiangiogenic therapy effects Wiltrud Lederle1*, Susanne Arns1, Anne Rix1, Felix Gremse1, Dennis Doleschel1, Jörn Schmaljohann2, Felix M Mottaghy2,3, Fabian Kiessling1 and Moritz Palmowski1,2,4 Abstract Background: Molecular apoptosis imaging is frequently discussed to be useful for monitoring cancer therapy.
10p
dauphong13
10-02-2012
45
6
Download
-
Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học quốc tế đề tài : Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer
14p
dauphong3
03-01-2012
52
6
Download
-
Antiangiogenic Therapy Understanding the molecular mechanisms that regulate tumor angiogenesis may provide unique opportunities for cancer treatment. Acquired drug resistance of tumor cells due to their high intrinsic mutation rate is a major cause of treatment failure in human cancers. ECs comprising the tumor vasculature are genetically stable and do not share genetic changes with tumor cells; the EC apoptosis pathways are therefore intact.
5p
konheokonmummim
03-12-2010
77
5
Download
CHỦ ĐỀ BẠN MUỐN TÌM
![](images/graphics/blank.gif)